Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial
Paul Welsh, Mark Woodward, Graham S Hillis, Qiang Li, Michel Marre, Bryan Williams, Neil Poulter, Louise Ryan, Stephen Harrap, Ansuhka Patel, John Chalmers, Naveed Sattar
DIABETES CARE | AMER DIABETES ASSOC | Published : 2014
OBJECTIVE: We investigated microvascular event risk in people with type 2 diabetes and assessed whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT) improved prediction. RESEARCH DESIGN AND METHODS: We performed a case-cohort study, including 439 incident cases of microvascular events (new or worsening nephropathy or retinopathy) and 2,946 noncase subjects identified from participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. NT-proBNP and hsTnT were measured in stored plasma samples using automated commercial assays. RESULTS: After adjustment for age, sex, an..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by NHMRC of Australia
Awarded by British Heart Foundation
The ADVANCE trial (clinical trial reg. no. NCT00145925, clinicaltrials.gov) was partially funded by the National Health and Medical Research Council (NHMRC) of Australia (project grant ID 211086 and program grants 358395 and 571281). The biomarker work in the current study was funded by the NHMRC of Australia (project grant 632507) and the Diabetes Australia Research Trust. P. W. is supported by British Heart Foundation fellowship FS/12/62/29889. B. W. is a National Institute for Health Research (NIHR) Senior Investigator and is supported by the NIHR University College London Biomedical Research Centre.